MedTrace Logo

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

NCT05288504 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2024-09-05

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).

Conditions

  • Non-Eosinophilic Asthma

Interventions

DRUG

AVTX-002

Dose of 600 mg administered subcutaneously three times during the study.

DRUG

Placebo

Placebo sourced as normal saline administered subcutaneously three times during the study.

Sponsors & Collaborators

  • Avalo Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Garry Neil, MD · Avalo Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2023-05-11
Completion
2023-05-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05288504 on ClinicalTrials.gov